SGLT-2 Inhibitors: Fighting Cardiovascular Disease Mortality in Diabetes

被引：0
作者：
Ghaffar, Zunaira Abdul
Anwar, Shahzad
Rizvi, Syed Wajih
机构：
[1] Dow Univ Hlth Sci, Dept Med, Dow Med Coll, Karachi, Pakistan
[2] Univ Med & Dent, Camden, NJ USA
来源：
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN | 2019年 / 29卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：195 / 195
页数：1
相关论文
共 50 条
  • [31] Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
    Aftab, Saba
    Suresh, Rishwanth Vetrivel
    Sherali, Nazleen
    Daniyal, Muhammad
    Tsouklidis, Nicholas
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (10)
  • [32] Impact of SGLT-2 inhibitors on modifiable cardiovascular risk factors in Romanian patients with type 2 diabetes mellitus
    Gherbon, Adriana
    Frandes, Mirela
    Dirpes, Darius
    Timar, Romulus
    Timar, Bogdan
    DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01)
  • [33] TO TREAT OR NOT TO TREAT - THE REAL IMPACT OF SGLT-2 INHIBITORS ON CARDIOVASCULAR RISK
    Timar, Bogdan
    Gaita, Laura
    Timar, Romulus
    INTERDIAB 2016: DIABETES MELLITUS AS CARDIOVASCULAR DISEASE, 2016, : 458 - 466
  • [34] Cardiovascular effectiveness of SGLT-2 inhibitors versus metformin as first-line treatment for type 2 diabetes
    Shin, Hojin
    Schneeweiss, Sebastian
    Glynn, Robert
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 42 - 42
  • [35] Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials
    Mannucci, Edoardo
    Dicembrini, Ilaria
    Nreu, Besmir
    Monami, Matteo
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2020, 30 (01) : 71 - 76
  • [36] SGLT-2 Inhibitors and Cardiovascular Risk An Analysis of CVD-REAL
    Cavender, Matthew A.
    Norhammar, Anna
    Birkeland, Kare I.
    Jorgensen, Marit Eika
    Wilding, John P.
    Khunti, Kamlesh
    Fu, Alex Z.
    Bodegard, Johan
    Blak, Betina T.
    Wittbrodt, Eric
    Thuresson, Marcus
    Fenici, Peter
    Hammar, Niklas
    Kosiborod, Mikhail
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (22) : 2497 - 2506
  • [37] Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
    El Hage, Lea
    Kashyap, Sangeeta R.
    Rao, Pratibha
    JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH, 2019, 10
  • [38] SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
    Androutsakos, Theodoros
    Nasiri-Ansari, Narjes
    Bakasis, Athanasios-Dimitrios
    Kyrou, Ioannis
    Efstathopoulos, Efstathios
    Randeva, Harpal S.
    Kassi, Eva
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (06)
  • [39] SGLT-2 inhibitors: Diabetes and CKD and CHF (and gout?), oh my!
    Mandell, Brian F.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2024, 91 (07) : 392 - 393
  • [40] Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
    Chavda, Vishal
    Vashi, Ruju
    Patel, Snehal
    CURRENT DRUG TARGETS, 2021, 22 (14) : 1629 - 1636
12345